The American Association of Orthopedic Surgeons (AAOS) has issued a new statement on the use of emerging biologic therapies. Like much of the discussion regarding orthobiologics, the AAOS statement touches on the need for regulation regarding safety and effectiveness of new uses of biologic therapies, particularly during the “increasing shift to therapeutic biologic products for restoring structure and function.”
Notably, AAOS encouraged surgeons to join and engage in orthobiologic registries. The statement reads: “Orthopaedic surgeons and their organizations/facilities should support and participate in orthopaedic registries and other data collection systems. Through voluntary reporting of key patient and orthopaedic treatment information to local, state and national repositories, both patient care and safety will be improved. Documentation and reporting are critical to establishing the body of evidence needed to demonstrate the safety and effectiveness of emerging biologics.”
The Regenerative Orthobiologics Registry (ROR), the official registry of TOBI: The Orthobiologic Institute, is rapidly growing in membership. Surgeons and physicians interested in contributing to and accessing patient and orthopaedic treatment information may fill out a membership application here.